Abbott Abbott Laboratories announced an agreement to acquire Exact Sciences Exact Sciences Corporation, valuing the transaction at about $21 billion. The deal will position Abbott to expand its cancer diagnostics leadership, combining Exact Sciences’ screening and precision oncology portfolio with Abbott’s broader healthcare capabilities. Exact Sciences shareholders will receive $105 per share in cash, and the transaction is expected to be immediately accretive to Abbott’s revenue growth and gross margin.
Key facts
- Parties: Abbott Laboratories (public; ticker ABT) and Exact Sciences Corporation (public; ticker EXAS).
- Offer: $105 per common share in cash for Exact Sciences, reflecting a total equity value around $21 billion.
- Strategic rationale: Enter and lead in fast-growing cancer diagnostics segments; expand access to early detection tools; accelerate innovation across cancer screening, precision oncology, and genetic testing.
Exact Sciences portfolio
- Core products include Cologuard for noninvasive colorectal cancer screening; Oncotype DX for breast cancer treatment decisions; Oncodetect for molecular residual disease; Cancerguard for multi-cancer early detection.
Context
- The transaction signals continued consolidation in the diagnostic and cancer-screening space, with growth expected from expanded access to screening and personalized treatment planning.
Авторское резюме: Abbott заключил соглашение о покупке Exact Sciences, создавая лидера в ранней диагностике рака и персонализированной онкологии на рынке с двузначным ростом.
more
Urban Milwaukee — 2025-11-20